Filtered By:
Condition: Hypertension
Nutrition: Vitamin K

This page shows you your search results in order of relevance. This is page number 6.

Order by Relevance | Date

Total 93 results found since Jan 2013.

Safety of once- or twice-daily dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with nonvalvular atrial fibrillation: A NOAC-TR study.
In this study, we investigated the adherence to once- or twice-daily dosing of NOACs and the risk of bleeding in nonvalvular atrial fibrillation (NVAF) patients. This multicenter cross-sectional study, conducted between 1 September 2015 and 28 February 2016, included 2214 patients receiving NOACs for at least 3 months, due to NVAF. Patients receiving once-daily or twice-daily NOAC doses were 1:1 propensity score matched for baseline demographic characteristics and the presence of other diseases. The medication adherence was assessed by the 8-item Morisky Medication Adherence Scale. Risk factors were investigated in relatio...
Source: Bosnian Journal of Basic Medical Sciences - October 3, 2017 Category: General Medicine Tags: Bosn J Basic Med Sci Source Type: research

Clinical profile and satisfaction with anticoagulated treatment in patients with non-valvular atrial fibrillation attended in Internal Medicine and Neurology departments of Spain.
CONCLUSIONS: Although there were some differences in the clinical profile of patients with atrial fibrillation attended in Neurology or Internal Medicine departments, all of them had many comorbidities and a high thromboembolic risk. Despite INR control was poor, the most common oral anticoagulant used were vitamin K antagonists. Satisfaction related to oral anticoagulation was high. PMID: 28990646 [PubMed - in process]
Source: Revista de Neurologia - October 12, 2017 Category: Neurology Tags: Rev Neurol Source Type: research

Use of non ‐vitamin K oral anticoagulants in people with atrial fibrillation and diabetes mellitus
ConclusionsThe efficacy and safety of non‐vitamin K oral anticoagulants compared with warfarin generally extend to participants with diabetes mellitus, although dedicated randomized trials or real‐world data are lacking.This article is protected by copyright. All rights reserved.
Source: Diabetic Medicine - February 13, 2018 Category: Endocrinology Authors: O. Itzhaki, B. Zadok, A. Eisen Tags: Review Source Type: research

Shifting to a non-vitamin K antagonist oral anticoagulation agent from vitamin K antagonist in atrial fibrillation
ConclusionIn a contemporary setting among VKA-experienced NVAF patients; VKA is still prevalent although about 30% by December 2015 had shifted to a NOAC.
Source: Europace - June 28, 2017 Category: Cardiology Source Type: research

Spontaneous choroidal hemorrhage associated with novel oral anticoagulants: A report of two cases and literature review.
We describe two clinical cases of spontaneous choroidal hemorrhage in patients treated with direct oral anticoagulants (rivaroxaban and dabigatran etexilate) for atrial fibrillation. These cases show that an ocular hemorrhagic risk exists with these drugs. Patients treated with DOAC should have the therapeutic dose adjusted based on creatinine clearance. Special monitoring should be performed in patients with age-related macular degeneration or with hypertension even though meta-analysis shows that the risk of intraocular bleeding is reduced by 22% compared with warfarin. PMID: 30213607 [PubMed - as supplied by publisher]
Source: Journal Francais d Ophtalmologie - September 16, 2018 Category: Opthalmology Tags: J Fr Ophtalmol Source Type: research

Which anticoagulants should be used for stroke prevention in non-valvular atrial fibrillation and severe chronic kidney disease?
Purpose of review Non-valvular atrial fibrillation is common in patients with severe chronic kidney disease (CKD) and historically patients have been treated with vitamin K antagonists (VKA). However, these agents have questionable efficacy and are associated with increased bleeding risk. Non-vitamin K oral anticoagulants (NOAC) have advantages over VKA in early stage CKD. In this review, we sought to establish evidence for best practice in patients with severe CKD (creatinine clearance
Source: Current Opinion in Nephrology and Hypertension - October 5, 2018 Category: Urology & Nephrology Tags: DIAGNOSTICS AND TECHNIQUES: Edited by Maarten W. Taal Source Type: research

Risk Factors, Co-Morbidities and Treatment of In-Hospital Patients with Atrial Fibrillation in Bulgaria.
CONCLUSIONS: Atrial fibrillation was highly prevalent among our study population. Reduced and mid-range left ventricular ejection fraction, valvular heart disease, and HTN were the risk factors with the strongest association with AF. Although a large number of our AF patients were administered antithrombotic treatment, the prescription rate of oral anticoagulants should be further improved. PMID: 30344265 [PubMed - in process]
Source: Medicina (Kaunas) - May 25, 2018 Category: Universities & Medical Training Authors: Naydenov S, Runev N, Manov E, Vasileva D, Rangelov Y, Naydenova N Tags: Medicina (Kaunas) Source Type: research

Recent evidence for direct oral anticoagulants in chronic kidney disease
Purpose of review The direct oral anticoagulants (DOACs) have emerged as an effective and safe alternative to vitamin K antagonists (VKAs) for stroke and venous thromboembolism (VTE) prevention. However, patients with chronic kidney disease (CKD) experience an increase in the risk of both thromboembolism and bleeding, and the risk–benefit profile of DOACs, particularly in advanced CKD remains a source of ongoing debate. This review summarizes the recent evidence on the effects of DOACs in CKD across a range of clinical indications including newly emerging indications. Recent findings Data on early-to-moderate stage ...
Source: Current Opinion in Nephrology and Hypertension - April 4, 2019 Category: Urology & Nephrology Tags: EPIDEMIOLOGY AND PREVENTION: Edited by Navdeep Tangri Source Type: research

Risk of left atrial appendage thrombus in patients with atrial fibrillation and chronic kidney disease.
CONCLUSIONS: Despite OAC, patients with concomitant AF and CKD remain at high risk for LAA thrombus formation. PMID: 32207840 [PubMed - as supplied by publisher]
Source: Cardiology Journal - March 23, 2020 Category: Cardiology Authors: Budnik M, Gawałko M, Gorczyca I, Uziębło-Życzkowska B, Krzesińki P, Kochanowski J, Scisło P, Michalska A, Jelonek O, Starzyk K, Jurek A, Kiliszek M, Wożakowska-Kapłon B, Gielerak G, Filipiak KJ, Opolski G, Kapłon-Cieślicka A Tags: Cardiol J Source Type: research

Comparison of effects of triple antithrombotic therapy and dual antiplatelet therapy on long-term outcomes of acute myocardial infarction
This study aimed to compare the long-term outcome of triple antithrombotic therapy (TAT) with that of dual antiplatelet therapy (DAPT) after AMI. This was a nationwide, propensity score-matched, case –control study of 186,112 first AMI patients, of whom 2,825 received TAT comprising aspirin, clopidogrel, and warfarin. Propensity score matching in a ratio of 1:4 by age, sex, comorbidities, and treatment was adopted, Finally, 2,813 AMI patients and 11,252 matched controls that were administered TAT and DAPT (aspirin and clopidogrel), respectively, were included in our analysis. The 12-year overall survival rate did not dif...
Source: Heart and Vessels - October 8, 2020 Category: Cardiology Source Type: research

Novel Bleeding Risk Score for Patients with Atrial Fibrillation on Oral Anticoagulants, including Direct Oral Anticoagulants.
CONCLUSION: In this prospective cohort study of AF patients and predominantly DOAC users, we successfully derived a bleeding risk prediction model with good calibration and discrimination. PMID: 33501722 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - January 27, 2021 Category: Hematology Authors: Adam L, Feller M, Syrogiannouli L, Del-Giovane C, Donzé J, Baumgartner C, Segna D, Floriani C, Roten L, Fischer U, Aeschbacher S, Moschovitis G, Schläpfer J, Shah D, Amman P, Kobza R, Schwenkglenks M, Kühne M, Bonati L, Beer J, Osswald S, Conen D, Auje Tags: J Thromb Haemost Source Type: research

Atrial thrombus detection on transoesophageal echocardiography in patients with atrial fibrillation undergoing cardioversion or catheter ablation: A pooled analysis of rates and predictors
ConclusionThe prevalence of LAT/LAAT in AF patients undergoing ECV or CA varies widely, mainly due to differences in patient risk profiles and OAC types. Further research should determine whether the predictors of LAT/LAAT detection identified by this study could be used to select patients who require preprocedural TEE.This article is protected by copyright. All rights reserved.
Source: Journal of Cardiovascular Electrophysiology - May 10, 2021 Category: Cardiology Authors: Jean Jacques Noubiap, Thomas A. Agbaedeng, Aude Laetitia Ndoadoumgue, Ulrich Flore Nyaga, Andre Pascal Kengne Tags: ORIGINAL ARTICLES Source Type: research

Maternal and neonatal complications in women with congenital heart disease: a nationwide analysis
ConclusionsThis population-based study illustrates a reassuringly low maternal mortality rate in a highly developed healthcare system. Nevertheless, maternal morbidity and neonatal morbidity/mortality were significantly increased in women with ACHD and their offspring compared to non-ACHD controls highlighting the need of specialized care and pre-pregnancy counselling.
Source: European Heart Journal - October 12, 2021 Category: Cardiology Source Type: research

Novel bleeding prediction model in atrial fibrillation patients on new oral anticoagulants
Conclusions We present a novel and simple risk score for prediction of major bleeding in patients with non-valvular AF treated with NOACs. Validation in additional cohorts is warranted.
Source: Heart - January 28, 2022 Category: Cardiology Authors: Barnett-Griness, O., Stein, N., Kotler, A., Saliba, W., Gronich, N. Tags: Editor's choice Arrhythmias and sudden death Source Type: research

COVID-19-Associated Coagulopathy: Role of Vitamins D and K
Curr Pharm Biotechnol. 2022 May 27. doi: 10.2174/1389201023666220527110455. Online ahead of print.ABSTRACTRecent reports show coagulopathy as a potential complication and poorer outcome of coronavirus disease 2019 (COVID-19), especially in those with comorbid conditions such as diabetes and hypertension as thrombosis could result in stroke and heart attacks. Indeed, cardiovascular complications in COVID-19 accounts for 40% of mortality. Although there is no standard treatment protocol or guidelines for COVID-19, it is a common practice to use anti-inflammatory corticosteroids and anti-coagulants, especially for severe COVI...
Source: Current Pharmaceutical Biotechnology - May 31, 2022 Category: Biotechnology Authors: Bruk Getachew Harold E Landis Kebreten F Menaye Yousef Tizabi Source Type: research